Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2.
Martin-Blondel G, Marcelin AG, Soulié C, Kaisaridi S, Lusivika-Nzinga C, Dorival C, Nailler L, Boston A, Melenotte C, Cabié A, Choquet C, Coustillères F, Martellosio JP, Gaube G, Trinh-Duc A, Ronchetti AM, Pourcher V, Chauveau M, Lacombe K, Peiffer-Smadja N, Housset P, Perrot A, Pialoux G, Martin A, Dubee V, Devaux M, Frey J, Cazanave C, Liblau R, Carrat F, Yordanov Y. Martin-Blondel G, et al. Among authors: kaisaridi s. J Infect. 2022 Oct;85(4):e104-e108. doi: 10.1016/j.jinf.2022.06.033. Epub 2022 Jul 5. J Infect. 2022. PMID: 35803386 Free PMC article. No abstract available.
Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study).
Martin-Blondel G, Marcelin AG, Soulié C, Kaisaridi S, Lusivika-Nzinga C, Dorival C, Nailler L, Boston A, Melenotte C, Gaube G, Choquet C, Liblau R, Carrat F, Yordanov Y; COCOPREV Study Group. Martin-Blondel G, et al. Among authors: kaisaridi s. J Infect. 2022 Jun;84(6):e101-e104. doi: 10.1016/j.jinf.2022.04.010. Epub 2022 Apr 7. J Infect. 2022. PMID: 35398409 Free PMC article. No abstract available.
Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir.
Martin-Blondel G, Marcelin AG, Soulié C, Kaisaridi S, Lusivika-Nzinga C, Zafilaza K, Dorival C, Nailler L, Boston A, Ronchetti AM, Melenotte C, Cabié A, Choquet C, Trinh-Duc A, Lacombe K, Gaube G, Coustillères F, Pourcher V, Martellosio JP, Peiffer-Smadja N, Chauveau M, Housset P, Piroth L, Devaux M, Pialoux G, Martin A, Dubee V, Frey J, Le Bot A, Cazanave C, Petua P, Liblau R, Carrat F, Yordanov Y. Martin-Blondel G, et al. Among authors: kaisaridi s. Clin Microbiol Infect. 2023 Apr;29(4):543.e5-543.e9. doi: 10.1016/j.cmi.2022.12.016. Epub 2022 Dec 28. Clin Microbiol Infect. 2023. PMID: 36586513 Free PMC article.
Construction and evaluation of an α-particle-irradiation exposure apparatus.
Nikitaki Z, Choulilitsa E, Kalospyros SA, Kaisaridi S, Terzoudi GI, Kokkoris M, Georgakilas AG. Nikitaki Z, et al. Among authors: kaisaridi s. Int J Radiat Biol. 2021;97(10):1404-1416. doi: 10.1080/09553002.2021.1962568. Epub 2021 Aug 17. Int J Radiat Biol. 2021. PMID: 34330206